-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $110

Benzinga·01/05/2026 15:28:34
Listen to the news
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $88 to $110.